- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objectives: The object of this study was to observe the suppressive effects of Yijintang-gamibang (YJGMB), Yijintang being traditionally used in the Korean Medicine for treating various digestive diseases, on the rat reflux esophagitis (RE) as compared with omeprazole, a well-known proton pump inhibitor. Methods: Three different dosages of YJGMB, 50, 100 and 200 mg/kg, were orally pretreated once a day for 28 days before pylorus and forestomach ligation. Seven groups of 8 rats each were used in the study. Six hrs after pylorus and forestomach ligation, changes to the stomach and esophagus lesion areas, gastric volumes, acid and pepsin outputs, invasive lesion percentages, fundic mucosa, esophageal submucosa and total thicknesses were measured by histomorphometry. The results were compared with omeprazole 10 and 30 mg/kg treated groups in which the effects on RE were already confirmed. Results: As results of pylorus and forestomach ligation, marked increases of esophageal and gastric mucosa lesion areas, gastric volumes, acid outputs, pepsin outputs were observed with histopathological changes of RE, such as hemorrhages, ulcerative lesions and edematous changes on the esophageal and fundic mucosa. However, these pylorus and forestomach ligation induced RE were dose-dependently inhibited by treatment of 50, 100 and 200 mg/kg of YJGMB. YJGMB 50 mg/kg showed similar suppressive effects as 30 mg/kg of omeprazole, but more favorable effects were observed as compared with omeprazole 10 mg/kg. Conclusion: The results suggest that YJGMB showed favorable suppressive effects on the RE induced by pylorus and forestomach ligation. It is therefore expected that YJGMB will show favorable effects on RE as corresponds to the suggestion of traditional Korean medicine. However, more detailed mechanism studies should be conducted in future with the screening of the biological active chemical compounds in herbs.
1 박인서. 근거중심의 소화기병학. 서울:군자출판사. 2002:33.
2 Choi MG. The prevalence of gastroes- ophageal reflux disease in Korea. Korean J Medicine. 2000;58(2):126-128.
3 전국의과대학교수. Current Medical Diagnosis & Treatment(1). 서울:한우리. 2000.
4 Colin-Jones DG. Histamine-2-receptor antagonists in gastroesophageal reflux. Gut. 1989;30(10): 1305-1308.
5 DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999;94(6): 1434-1442.
6 이상열. 위식도 역류질환의 생물정신사회적 이 해와 삶의 질. 대한소화관운동학회지. 2001;7(2): 367-374.
7 全國韓醫科大學脾系內科學敎授共著. 脾系內科學. 서울:圖書出版東友. 2000.
8 張機 著. 仲景全書. 大北:集文書國. 1983.
9 許浚. 東醫寶鑑. 서울:南山堂. 1979:436-438.
10 김행애. 二陳湯이 白鼠 胃運動 및 胃液分泌에 미치는 影響. 익산: 圓光大學校大學院; 1990.
11 Choi JW, Lee CH, Ko BM, Lee KG. Effects of Yijin-tang Extract on the Immunoreactive Cells of gastrin, Histamine and Somatostatin in Rats Stomach. Korean J. Oriental Medical Physiology & Pathology. 2001;15(4):554-559.
12 장태수. 이진탕의 진통 진경 소염 및 GASTRIN과 UROPEPSIN의 분비에 미치는 영향. 東西醫學. 1982;7(1):46-48.
13 Hwang JY, Kim DJ, Byun JS. Effect of Yijintang-gamibang and Omeparzole Extracts on Reflux Oesophagitis Induced by Pylorus and Forestomach Ligation in Rat. Korean J. Oriental Medical Physiology & Pathology. 2009;23(5): 1073-1079.
14 Oh JH, Kim BS, Lim HY, Kim DW, Choi BH, Hur JI, et al. Three cases report of functional dyspepsia patients who were administered by Lijintang-gamibang. Korean J. Orient. Int. Med. 2005;26(3):641-651.
15 Kim BS, Lim HY, Oh JH, Kim DW, Choi BH, Hur JI, et al. Seven cases of non-erosive gastroesophageal reflux disease who were treated by Lijintang -gamibang and acupuncture. Korean J. Orient. Int. Med. 2005;26(4):926-934.
16 Hong MW. Pharmaceutical investigation of fossil shell Crassostrea gravitesta eoilensis Kim et Noda. Korean J Pharmacog. 1973;4(1):9-17.
17 Department of Health, Education and Welfare Publication. National Institute of Health. 1985; 85-23.
18 Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and alpha-tocopherol, an antioxidant vitamin on experimental reflux oesophagitis in rats. Eur J Pharmacol. 2008;589(1/3):233-238.
19 Nakamura K, Ogawa Y, Furuta Y, Miyazaki H. Effects of sodium polyacrylate (PANa) on acute esophagitis by gastric juice in rats. Jpn J Pharmacol. 1982;32:445-456.
20 Nagahama K, Yamato M, Kato S, Takeuchi K. Protective effect of lafutidine, a novel H2-receptor antagonist, on reflux esophagitis in rats through capsaicin-sensitive afferent neurons. J Pharmacol Sci. 2003;93(1):55-61.
21 Sairam K, Rao CV, Dora BM, Kumar KV, Agrawal VK, Goel RK. Antiulcerogenic effect of methanolic extract of Emblica officinalis: an experimental study. J Ethnopharmacol. 2002; 82(1):1-9.
22 Johnson F, Joelsson B, Gudmundsson K, Grieff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1987;58:163-174.
23 Castell DO. Medical therapy for reflux esophagitis: 1986 and beyond. Annals of internal medicine.1986;104(1):112-114.
24 Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in Veteran. N Eng J Med. 1992;326(12): 786-792.
25 黃帝內經素問. 서울:成輔社. 1975:685-712.
26 劉完素. 劉河間三六書. 서울:成輔社. 1976:403.
27 李杲. 東垣十種醫書. 서울:慶熙大漢醫學院. 1976: 518-519.
28 聾廷賢, 萬病回春. 서울:杏林書院. 1972:159-162.
29 張介賓. 景岳全書. 上海:上海科學技術出版社. 1984: 377-381.
30 李梴. 醫學入門. 서울:翰成社. 1983:455,465, 497.
31 聾廷賢. 壽世保元. 上海:上海科學技術出版社. 1989: 193-197.
32 上海中醫學院附屬光醫院編著. 現代中醫內科手 冊. 江蘇科學技術出版社. 1996:454.
33 원광대학교비계내과학교실편. 신비계내과학. 원광대학교출판부. 1996:191-198.
34 宋 太平惠民和劑局編. 太平惠民和劑局方. 北京: 人民衛生出版社. 1985:141.
35 鞠潤範, 金相贊, 朴宣東, 朴性奎, 徐富一, 徐榮培, 申舜植, 李尙仁, 李長泉, 李棣熙, 鄭宗佶, 朱榮丞, 崔湖榮. 方劑學. 서울:圖書出版永林社. 2008: 528-531.
36 김창민 외. 중약대사전. 서울:도서출판 정담. 1997.
37 한의학대사전편찬위원회. 한의학대사전. 서울: 도서출판 정담. 1998.
38 Park SM, Zhao RJ, Lee JR, Lee CW, Kim HJ, Kwon YK, et al. Inhibitory effect of Oyster conchioloin on pro-inflammatory mediator in lipopolysaccharide - activated RAW 264.7 cells. Korean J. Oriental Medical Physiology & Pathology. 2008;22(4):878-883.
39 Nagahama K, Yamato M, Nishio H, Takeuchi K. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis Sci. 2006;51: 303-309.
40 Min YS, Bai KL, Yim SH, Lee YJ, Song HJ, Kim JH, et al. The effect of luteolin-7-O-beta- D-glucuronopyranoside on gastritis and esophagitis in rats. Arch Pharm Res. 2006;29(6):484-489.
41 Duarte CG, dos Santos GL, Azzolini AE, de Assis Pandochi AI. The effect of the antithyroid drug propylthiouracil on the alternative pathway of complement in rats. Int J Immunopharmacol. 2000;22(1):25-33.
42 Pinzone, Fox ML, Sastry MK, Parenti DM, Simon GL. Plasma leptin concentration increases early during highly active antiretroviral therapy for acquired immunodeficiency syndrome, independent of body weight. J Endocrinol Invest. 2005;28(3):1-3
43 Spelman K, Burns J, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators. Altern Med Rev. 2006;11(2):128-147.
44 Chang HH, Yeh CH, Sheu F. A novel immunomodulatory protein from Poria cocos induces Toll-like receptor 4-dependent activation within mouse peritoneal macrophages. J Agric Food Chem. 2009;57(14):6129-6139.
45 Chan WK, Law HK, Lin ZB, Lau YL, Chan GC. Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. Int Immunol. 2007; 19(7):891-899.
46 Cheng A, Wan F, Wang J, Jin Z, Xu X. Macrophage immunomodulatory activity of polysaccharides isolated from Glycyrrhiza uralensis Fish. Int Immunopharmacol. 2008;8(1): 43-50.
47 Gaynor EB. Otolaryngologic manifestations of gastroesophageal reflux. Am J Gastroenterol. 1991;86:801-808.
48 DeMeester TR, Wernly JA, Bryant GH, Little AG, Skinner DB. Clinical and in vitro analysis of determinants of gastroesophageal competence: a study of the principles of antireflux surgery. Am J Surg. 1979;137(1):39-46.
49 Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999; 159(7):649-657.
50 Klinkenberg-Knol EC, Jansen JBMJ, Lamers CBHQ, Neils F, Snel P, Meuwissen SGM. Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists. Scand J Gastroenterol. 1989;Suppl 166:88-93.
51 Inatomi N, Nagaya H, Takami K, Shino A, Satoh H. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn J Pharmacol. 1991;55: 437-451.
52 Gartner LP, Hiatt JL. Color Textbook of Histology, third edition, Elsevier:Philadelphia, pp 381-411, 2007.
53 Castell DO, Murray JA, Tutuian R, Orlando RC, Arnold R. Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations. Aliment Pharmacol Ther. 2004; 20(Suppl 9):14-25.
54 Wang C, Hunt RH. Precise role of acid in non-erosive reflux disease. Digestion. 2008;78 (Suppl 1):31-41.
55 Kim JM, Choi SM, Kim DH, Oh TY, Ahn BO, Kwon JW, et al. Combined use of omeprazole and a novel antioxidative cytoprotectant for the treatment of peptic ulcer. Facilitation of ulcer healing in experimental animals. Arzneimittel Forschung. 2005;55(7):387-393.
56 Kuroiwa Y, Okamura T, Ishii Y, Umemura T, Tasaki M, Kanki K, et al. Enhancement of esophageal carcinogenesis in acid reflux model rats treated with ascorbic acid and sodium nitrite in combination with or without initiation. Cancer Sci. 2008;99(1):7-13.